Pixelgen closes $15.5 million Series B round
Led by Flat Capital, the funding scales Proxiome Kit commercialization and appoints two new directors to guide strategic growth.
See the latest news and media coverage for Pixelgen. We track all announcements, press releases, and industry mentions in real time, all in one place.
Single-cell protein interactomics technology company
pixelgen.comLast updated
In short: Pixelgen raised $15.5M in Series B funding, won a $14.7M EU grant, launched its Proxiome Kit, and advanced immuno-oncology partnerships.
Led by Flat Capital, the funding scales Proxiome Kit commercialization and appoints two new directors to guide strategic growth.
He brings over two decades of life sciences experience to drive global adoption of the Proxiome Kit and advance protein interactomics research.
The collaboration provides US researchers with streamlined access to the Proxiome Kit for protein interactomics analysis. This partnership accelerates translational research in immuno-oncology and cell therapy.
The capital accelerates Proxiome Kit development for cellular interaction studies and advances precision medicine research across multiple therapeutic fields.
A selection of the main news from Sweden's startup and tech sector. All – and many more – have previously been covered in more detail...
The investment company Flat Capital is investing approximately 40 million kronor in Pixelgen Technologies and leads the company's financing round of approximately 150...
Funding to accelerate platform expansion into new applications in cell-to-cell interactions and tissue STOCKHOLM, June 30, 2025 /PRNewswire/ -- Pixelgen Technologies today announced that it...
STOCKHOLM, Oct. 9, 2023 /PRNewswire/ -- Pixelgen Technologies ®, a leader in spatial proteomics for single cells, announced today that it has closed a Series...
Track Pixelgen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.